Preclinical studies suggested poor bioavailability with a consequent in vivo ineffectiveness for compound 182a [2, 97],
while compound 182b entered clinical trials, unfortunately its development was soon suspended [98, 99].
The endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7
While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in
preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.